<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00207220</url>
  </required_header>
  <id_info>
    <org_study_id>2003P-001769</org_study_id>
    <nct_id>NCT00207220</nct_id>
  </id_info>
  <brief_title>Ventricular-Vascular Coupling in Heart Failure</brief_title>
  <official_title>Ventricular-Vascular Coupling in Patients With Heart Failure and Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that increases in ventricular-vascular stiffness can be&#xD;
      demonstrated by arterial tonometry and echocardiography in subjects with heart failure with&#xD;
      preserved ejection fraction (HF-nlEF)(i.e. normal left ventricular function.) We will also&#xD;
      track changes in pulsatile hemodynamics over time in subjects hospitalized with HF-nlEF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pathophysiologic mechanisms responsible for the development of heart failure in people&#xD;
      with preserved ejection fraction (i.e. normal left ventricular function) remain poorly&#xD;
      understood. One possible mechanism may be the contribution of increased arterial stiffness to&#xD;
      changes in pulsatile hemodynamic load during ventricular systole, implicating abnormal&#xD;
      ventricular-vascular interactions throughout the cardiac cycle in the pathogenesis of heart&#xD;
      failure with normal ejection fraction.&#xD;
&#xD;
      To investigate changes in ventricular-vascular stiffness in subjects with heart failure and&#xD;
      normal left ventricular function, comparisons will be made between 3 distinct&#xD;
      sub-populations:&#xD;
&#xD;
        -  subjects with heart failure and normal ejection fraction&#xD;
&#xD;
        -  non-diabetic hypertensive controls&#xD;
&#xD;
        -  normotensive controls&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">53</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>subjects with heart failure and normal ejection fraction non-diabetic hypertensive controls hypertensive diabetic controls normotensive controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>arterial tonometry</intervention_name>
    <description>used to determine peripheral arterial vascular tone by measuring blood pressure waveforms via a probe attached to the finger.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>PAT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>echocardiography</intervention_name>
    <description>ultrasound test using sound waves to create a moving picture of the heart</description>
    <arm_group_label>3</arm_group_label>
    <other_name>cardiac echo</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adults with heart failure and preserved left ventricular function&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects with heart failure and preserved ejection fraction&#xD;
&#xD;
          -  clinical signs of heart failure&#xD;
&#xD;
          -  serum brain natriuretic peptide (BNP) &gt;100pg/mL&#xD;
&#xD;
          -  NYHA functional class II-IV&#xD;
&#xD;
          -  left ventricular ejection fraction(LVEF) &gt;=50% measured by echocardiography&#xD;
&#xD;
          -  Non-diabetic subjects with hypertension&#xD;
&#xD;
          -  treated or untreated essential hypertension&#xD;
&#xD;
          -  LVEF &gt;=50% measured by echocardiography&#xD;
&#xD;
        Diabetic subjects with hypertension&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  treated or untreated essential hypertension&#xD;
&#xD;
          -  LVEF &gt;=50% measured by echocardiography&#xD;
&#xD;
        Normotensive control subjects&#xD;
&#xD;
          -  normal blood pressure (i.e. &lt; 140/90 mmHg)&#xD;
&#xD;
          -  LVEF &gt;=50% measured by echocardiography&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects with heart failure and preserved ejection fraction&#xD;
&#xD;
          -  atrial fibrillation&#xD;
&#xD;
          -  symptoms of angina or a myocardial infarction (MI) within 6 months&#xD;
&#xD;
          -  known significant coronary artery disease (CAD) (stenosis &gt; 70%)&#xD;
&#xD;
          -  significant valvular heart disease&#xD;
&#xD;
          -  restrictive/constrictive heart disease&#xD;
&#xD;
          -  inability to lie flat for procedure (estimated duration 1 hour)&#xD;
&#xD;
        Non-diabetic subjects with hypertension&#xD;
&#xD;
          -  atrial fibrillation&#xD;
&#xD;
          -  symptoms of angina or a myocardial infarction (MI) within 6 months&#xD;
&#xD;
          -  known significant coronary artery disease (CAD) (stenosis &gt; 70%)&#xD;
&#xD;
          -  significant valvular heart disease&#xD;
&#xD;
          -  restrictive/constrictive heart disease&#xD;
&#xD;
          -  inability to lie flat for procedure (estimated duration 1 hour)&#xD;
&#xD;
          -  prior history of heart failure or unexplained dyspnea&#xD;
&#xD;
        Diabetic subjects with hypertension&#xD;
&#xD;
          -  atrial fibrillation&#xD;
&#xD;
          -  symptoms of angina or a myocardial infarction (MI) within 6 months&#xD;
&#xD;
          -  known significant coronary artery disease (CAD) (stenosis &gt; 70%)&#xD;
&#xD;
          -  significant valvular heart disease&#xD;
&#xD;
          -  restrictive/constrictive heart disease&#xD;
&#xD;
          -  inability to lie flat for procedure (estimated duration 1 hour)&#xD;
&#xD;
          -  prior history of heart failure or unexplained dyspnea&#xD;
&#xD;
        Normotensive control subjects&#xD;
&#xD;
          -  prior history of structural heart disease or ventricular hypertrophy&#xD;
&#xD;
          -  treatment with HMG-Co(A)reductase inhibitors (statins)&#xD;
&#xD;
          -  anti-hypertensive medications&#xD;
&#xD;
          -  cigarette smoking&#xD;
&#xD;
          -  cocaine use&#xD;
&#xD;
          -  excessive alcohol intake&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Creager, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Akshay S. Desai, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>November 7, 2007</last_update_submitted>
  <last_update_submitted_qc>November 7, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2007</last_update_posted>
  <keyword>heart failure</keyword>
  <keyword>preserved ejection fraction</keyword>
  <keyword>vascular stiffness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

